Home » Stocks » ATNM

Actinium Pharmaceuticals, Inc. (ATNM)

Stock Price: $7.23 USD -0.06 (-0.82%)
Updated May 10, 2021 2:31 PM EDT - Market open
Market Cap 140.30M
Revenue (ttm) n/a
Net Income (ttm) -22.22M
Shares Out 12.13M
EPS (ttm) -1.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $7.23
Previous Close $7.29
Change ($) -0.06
Change (%) -0.82%
Day's Open 7.34
Day's Range 7.14 - 7.40
Day's Volume 67,250
52-Week Range 5.22 - 19.47

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, March 31, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that it will be participating in the Cell & Gene Meeting on t...

1 month ago - PRNewsWire

NEW YORK, March 25, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that initial patient enrollment in the second dose cohort in ...

1 month ago - PRNewsWire

INDIANAPOLIS--(BUSINESS WIRE)--Anthem, Inc. (NYSE: ATNM) today announced that the company has entered into an agreement to acquire myNEXUS, Inc. (“myNEXUS”), a comprehensive home-based nursing managemen...

1 month ago - Business Wire

NEW YORK, March 24, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that its collaborator, Memorial Sloan Kettering Cancer Center...

1 month ago - PRNewsWire

NEW YORK, March 11, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that preclinical feasibility data supporting an Actinium-225-...

1 month ago - PRNewsWire

NEW YORK, March 2, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that management will participate in the H.C. Wainwright (HCW) Global Life Scienc...

2 months ago - PRNewsWire

NEW YORK, Feb. 11, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today highlighted its presence at the 2021 Transplantation & Cellular Therapy (...

2 months ago - PRNewsWire

NEW YORK, Feb. 10, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that management will participate in the BIO CEO & Investor conf...

3 months ago - PRNewsWire

NEW YORK, Jan. 20, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that members of its executive team will participate in a fireside chat at the B....

3 months ago - PRNewsWire

NEW YORK, Jan. 13, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced the research collaboration with Astellas Pharma Inc. (TSE:4503) ("Astellas") to ...

3 months ago - PRNewsWire

NEW YORK, Dec. 29, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that the independent Data Monitoring Committee (DMC) has comple...

4 months ago - PRNewsWire

Actinium Pharmaceuticals (ATNM) closed the most recent trading day at $11.22, moving +0.9% from the previous trading session.

4 months ago - Zacks Investment Research

Actinium Pharmaceuticals (ATNM) closed the most recent trading day at $11.40, moving -1.04% from the previous trading session.

4 months ago - Zacks Investment Research

In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $11.11, marking a +0.63% move from the previous day.

5 months ago - Zacks Investment Research

NEW YORK, Dec. 9, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that it will be participating in the Targeted Radiopharmaceutica...

5 months ago - PRNewsWire

NEW YORK, Dec. 7, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that safety data from its ongoing pivotal Phase 3 SIERRA trial o...

5 months ago - PRNewsWire

Additional early stage results continue to be promising. The cash balance is adequate.

5 months ago - Seeking Alpha

In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $10.35, marking a +0.78% move from the previous day.

5 months ago - Zacks Investment Research

NEW YORK, Nov. 23, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today highlighted its intellectual property portfolio for apamistamab, a CD45 t...

5 months ago - PRNewsWire

In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $11.16, marking a -1.06% move from the previous day.

5 months ago - Zacks Investment Research

NEW YORK, Nov. 19, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced the appointment of Avinash Desai, MD, to the position of Executive Vice Presiden...

5 months ago - PRNewsWire

NEW YORK, Nov. 16, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it will be participating in the Alliance Global Partners' Virtual Healthcar...

5 months ago - PRNewsWire

Actinium Pharmaceuticals (ATNM) closed at $12.01 in the latest trading session, marking a +0.5% move from the prior day.

5 months ago - Zacks Investment Research

NEW YORK, Nov. 4, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that two abstracts on the Company's Antibody Radiation Conjugate (ARC) Iomab-B we...

6 months ago - PRNewsWire

NEW YORK, Nov. 4, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that data from the Phase 1 portion of the Actimab-A venetoclax Phase 1/2 combinat...

6 months ago - PRNewsWire

Is (ATNM) Outperforming Other Medical Stocks This Year?

6 months ago - Zacks Investment Research

NEW YORK, Oct. 14, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced the launch of its new research and development lab facility in ...

6 months ago - PRNewsWire

In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $10.15, marking a +1.2% move from the previous day.

7 months ago - Zacks Investment Research

Their targeted approach to bone marrow transplant conditioning has shown early signs of significantly improving on the poor outcomes seen with current non-targeted therapies.

7 months ago - Seeking Alpha

Actinium Pharmaceuticals (ATNM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

8 months ago - Zacks Investment Research

Is (ATNM) Outperforming Other Medical Stocks This Year?

8 months ago - Zacks Investment Research

NEW YORK, Aug. 10, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.

9 months ago - PRNewsWire

Does Actinium Pharmaceuticals (ATNM) have what it takes to be a top stock pick for momentum investors? Let's find out.

9 months ago - Zacks Investment Research

In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $0.59, marking a -1.67% move from the previous day.

9 months ago - Zacks Investment Research

Actinium's (ATNM) lead candidate, Iomab-B, being evaluated for acute myeloid leukemia will be in focus when the company reports second-quarter earnings.

9 months ago - Zacks Investment Research

Investors need to pay close attention to Actinium Pharmaceuticals (ATNM) stock based on the movements in the options market lately.

9 months ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Actinium Pharmaceuticals, Inc. (ATNM).

9 months ago - Zacks Investment Research

Actinium Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

9 months ago - Zacks Investment Research

Here we discuss four small stocks from the drug sector, which hold potential for a good run amid the coronavirus crisis.

Other stocks mentioned: ALPN, PCRX, TBIO
10 months ago - Zacks Investment Research

Investors need to pay close attention to Actinium Pharmaceuticals (ATNM) stock based on the movements in the options market lately.

10 months ago - Zacks Investment Research

Actinium Pharmaceuticals (ATNM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

10 months ago - Zacks Investment Research

Actinium Pharmaceuticals (ATNM) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

11 months ago - Zacks Investment Research

Actinium (ATNM) treats first patient in the third and final cohort of the Actimab-A and CLAG-M combination phase I study to treat relapsed or refractory acute myeloid leukemia.

1 year ago - Zacks Investment Research

Investors will focus on revenue growth and other pipeline updates, when Actinium (ATNM) reports fourth-quarter 2019 results.

1 year ago - Zacks Investment Research

Actinium (ATNM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 year ago - Zacks Investment Research

Actinium (ATNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

About ATNM

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19 CAR T-cell therapy with memorial sloan kettering cancer center. The company is also developing a mu... [Read more...]

Industry
Biotechnology
Founded
2000
CEO
Sandesh Seth
Employees
32
Stock Exchange
NYSEAMERICAN
Ticker Symbol
ATNM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for ATNM stock is "Buy." The 12-month stock price forecast is 36.75, which is an increase of 408.30% from the latest price.

Price Target
$36.75
(408.30% upside)
Analyst Consensus: Buy